ArticleFrontiers in medicine2026
Fusion of genomic and pathological data for breast cancer detection using BCDNN.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background of study: Breast cancer is one of the leading causes of mortality among women worldwide. Early and accurate detection is crucial for improving treatment outcomes and survival rates. Recent advancements in Deep Learning (DL), Artificial and Intelligence (AI), have shown promising results in medical image analysis and cancer prediction. Purpose: This study aims to develop and evaluate a BCDNN model that classifies tumors as benign or malignant using genomic and histopathological data. The research focuses on improving diagnostic accuracy through AI-driven methods. Method: The proposed BCDNN model was implemented in MATLAB R2016. A publicly available breast cancer dataset from Kaggle was used, encompassing both genomic and pathological features. The dataset was pre-processed and feature selected before training the BCDNN with optimized hyperparameters. Result: The proposed model achieved a mean classification accuracy of 93.84% during cross-validation, demonstrating stable, reliable performance in distinctive between benign and malignant cases. Conclusion: The BCDNN model shows significant promise in supporting clinical decision-making for breast cancer diagnosis. Future work may enhance model generalizability and explore integration with real-time diagnostic systems, contributing to better health outcomes for women globally. The code for this study is available on GitHub.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.